BR112023020856A2 - Uso de anticorpo para pd-1 e método de tratamento para uma neoplasia maligna - Google Patents
Uso de anticorpo para pd-1 e método de tratamento para uma neoplasia malignaInfo
- Publication number
- BR112023020856A2 BR112023020856A2 BR112023020856A BR112023020856A BR112023020856A2 BR 112023020856 A2 BR112023020856 A2 BR 112023020856A2 BR 112023020856 A BR112023020856 A BR 112023020856A BR 112023020856 A BR112023020856 A BR 112023020856A BR 112023020856 A2 BR112023020856 A2 BR 112023020856A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- malignant neoplasm
- carboplatin
- cisplatin
- subject
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 229930012538 Paclitaxel Natural products 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 4
- 229960004562 carboplatin Drugs 0.000 abstract 4
- 190000008236 carboplatin Chemical compound 0.000 abstract 4
- 229960004316 cisplatin Drugs 0.000 abstract 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 4
- 229940127089 cytotoxic agent Drugs 0.000 abstract 4
- 229960001592 paclitaxel Drugs 0.000 abstract 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 4
- 229940121482 prolgolimab Drugs 0.000 abstract 3
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 abstract 2
- 101150030763 Vegfa gene Proteins 0.000 abstract 2
- 229960000397 bevacizumab Drugs 0.000 abstract 2
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
uso de anticorpo para pd-1 e método de tratamento para uma neoplasia maligna. a presente invenção refere-se ao uso de anticorpo para pd-1, em particular prolgolimabe, em combinação com pelo menos um agente quimioterápico, em particular paclitaxel, carboplatina ou cisplatina, para o tratamento de uma neoplasia maligna em um sujeito que dele necessite, e ao uso do anticorpo para pd-1 prolgolimabe em combinação com anticorpo para vegf, em particular bevacizumabe, e pelo menos um agente quimioterápico, em particular paclitaxel, carboplatina ou cisplatina, para tratar uma neoplasia maligna em um sujeito que dele necessite. a presente invenção refere-se ainda a um método para tratar uma neoplasia maligna em um sujeito com necessidade do mesmo, compreendendo a administração de uma quantidade terapeuticamente eficaz de anticorpo para pd-1, em particular progolimabe, em combinação com pelo menos um agente quimioterápico, em particular paclitaxel, carboplatina ou cisplatina, e a um método para tratar uma neoplasia maligna em um sujeito com necessidade do mesmo, compreendendo a administração de uma quantidade terapeuticamente eficaz do anticorpo para pd-1 prolgolimabe em combinação com anticorpo para vegf, em particular bevacizumabe, e pelo menos um quimioterápico agente, em particular paclitaxel, carboplatina ou cisplatina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021109765A RU2787457C2 (ru) | 2021-04-08 | Способ лечения злокачественного новообразования с использованием комбинации антитела к pd-1 и химиотерапевтического агента | |
| PCT/RU2022/050122 WO2022216184A1 (en) | 2021-04-08 | 2022-04-08 | Malignant neoplasis treatment using pd-1 antibody combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020856A2 true BR112023020856A2 (pt) | 2024-02-06 |
Family
ID=83546621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020856A BR112023020856A2 (pt) | 2021-04-08 | 2022-04-08 | Uso de anticorpo para pd-1 e método de tratamento para uma neoplasia maligna |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4319736A1 (pt) |
| CN (1) | CN117500493A (pt) |
| AR (1) | AR125322A1 (pt) |
| BR (1) | BR112023020856A2 (pt) |
| CL (1) | CL2023003012A1 (pt) |
| CO (1) | CO2023013510A2 (pt) |
| EC (1) | ECSP23076237A (pt) |
| MA (1) | MA62924A1 (pt) |
| TW (1) | TW202304511A (pt) |
| UY (1) | UY39724A (pt) |
| WO (1) | WO2022216184A1 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080193448A1 (en) * | 2005-05-12 | 2008-08-14 | Pfizer Inc. | Combinations and Methods of Using an Indolinone Compound |
| CA3133821A1 (en) * | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
-
2022
- 2022-04-08 MA MA62924A patent/MA62924A1/fr unknown
- 2022-04-08 AR ARP220100896A patent/AR125322A1/es unknown
- 2022-04-08 BR BR112023020856A patent/BR112023020856A2/pt unknown
- 2022-04-08 WO PCT/RU2022/050122 patent/WO2022216184A1/en active Application Filing
- 2022-04-08 CN CN202280027483.7A patent/CN117500493A/zh active Pending
- 2022-04-08 TW TW111113464A patent/TW202304511A/zh unknown
- 2022-04-08 UY UY0001039724A patent/UY39724A/es unknown
- 2022-04-08 EP EP22785065.8A patent/EP4319736A1/en active Pending
-
2023
- 2023-10-06 CL CL2023003012A patent/CL2023003012A1/es unknown
- 2023-10-06 EC ECSENADI202376237A patent/ECSP23076237A/es unknown
- 2023-10-12 CO CONC2023/0013510A patent/CO2023013510A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA62924A1 (fr) | 2024-03-29 |
| WO2022216184A1 (en) | 2022-10-13 |
| TW202304511A (zh) | 2023-02-01 |
| ECSP23076237A (es) | 2024-01-31 |
| CL2023003012A1 (es) | 2024-04-12 |
| CN117500493A (zh) | 2024-02-02 |
| UY39724A (es) | 2022-10-31 |
| CO2023013510A2 (es) | 2023-11-10 |
| AR125322A1 (es) | 2023-07-05 |
| EP4319736A1 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018069732A2 (pt) | métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor | |
| BR112021022812A2 (pt) | Dosagem de inibidor de kras para tratamento de cânceres | |
| BR112022004474A2 (pt) | Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| BR112022026236A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr | |
| BR112015018549A2 (pt) | métodos de tratamento de deficiência de ferro com pirofosfato férrico solúvel | |
| BR112022018251A2 (pt) | Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma | |
| BR112023020856A2 (pt) | Uso de anticorpo para pd-1 e método de tratamento para uma neoplasia maligna | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| CR20230128A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
| BR112023006364A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe | |
| BR112023021913A2 (pt) | Tratamento de câncer com inibidor de raf | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| BR112023004830A2 (pt) | Métodos para tratamento de mieloma múltiplo | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| BR112019004906A2 (pt) | combinação incluindo abx196 para o tratamento de câncer | |
| BR112022021956A2 (pt) | Métodos, terapias e usos para o tratamento de câncer | |
| BR112022025801A2 (pt) | Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação | |
| BR112022010278A2 (pt) | Terapia combinada que envolve compostos macrocíclicos de diarila | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| BR112021018930A2 (pt) | Miriquizumabe para uso em um método de tratamento de doença de crohn | |
| MX2023006404A (es) | Terapia combinada de anticuerpos y taxanos. | |
| BR112023027006A2 (pt) | Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação | |
| BR112022023254A2 (pt) | Monoterapias e terapias de combinação | |
| MX2021004640A (es) | Tratamiento de la deficiencia de hierro con carboximaltosa ferrica. |